drugset / Trial / NCT03373903

Dose Finding Study to Determine if BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in the Elderly

NCT03373903

Phase 2 Active not recruiting 652 enrolled Restorbio Inc.
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to evaluate the efficacy, tolerability, and safety of BEZ235 alone and in combination with RAD001 to support further development to reduce the incidence of respiratory tract infections (RTIs) in elderly subjects.

Timeline

Start
2017-11-15
Primary completion
2018-05-03
Completion
2018-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Dactolisib Small molecule 5 mg Oral
Subject Dactolisib Small molecule 10 mg Oral
Subject Everolimus Small molecule 0.1 mg Oral